Background
Chronic kidney disease (CKD) is common and continues to increase. It is a risk factor for end-stage renal disease (ESRD) and is also a strong risk factor for cardiovascular diseases and mortality. A combined effect of environment and genotype determines the risk of CKD [
1‐
3], and cytokine polymorphisms play important roles [
3‐
5].
Cytokines are known to influence atherosclerosis, which causes CKD and subsequent ESRD [
6,
7]. The balance between pro- and anti-inflammatory cytokines determines the inflammatory response and may mediate the progression of CKD [
6]. Among the cytokines, pro-inflammatory (IL-1, IL-6, and TNF-α) and anti-inflammatory (IL-4, IL-10, and IL-13) cytokines play pivotal roles [
6]. IL-2 and IL-8 are also well-known pro-inflammatory cytokines that may affect CKD or ESRD progression [
7,
8]. Functional SNPs within the promoter area of these cytokine genes have been identified in that they influence the gene promoter activities and gene product levels [
9,
10]. Such polymorphisms have been demonstrated to be associated with susceptibility to a number of atherosclerotic diseases in CKD [
3‐
5], but the issue of whether these cytokine polymorphisms are risk factors for CKD itself has not been fully clarified. Some studies have failed to show such associations, possibly owing to the small sample sizes, and their conclusions are controversial [
11].
This study aimed to explore the associations between common potential functional promoter polymorphisms of pro-/anti-inflammatory cytokines and kidney function/CKD prevalence in a large Japanese population.
Results
The characteristics and the genotype frequencies of the subjects are summarised in Table
1 and Table
2. Seven subjects had a history of kidney disease, and two were categorised into the CKD group. The genotype frequencies were in Hardy-Weinberg equilibrium (data not shown), except for
IL6 C-572G (57.5% for CC, 35.7% for CG, and 6.8% for GG, P = 0.026, in comparison with the expected values of 57.2%, 36.9%, and 5.9%, respectively) [
13].
Table 1
Clinical characteristics of study subjects
Age (years) | 60.6 ± 7.2 | 55.9 ± 8.7 | 56.7 ± 8.6 |
Male | 252(46.2%) | 1,364(49.1%) | 1,616(48.6%) |
Body mass index | 23.5 ± 3.1 | 23.4 ± 3.3 | 23.4 ± 3.3 |
Hypertension | 245(44.9%) | 1,050(37.8%) | 1,295(39.0%) |
Systolic blood pressure (mm Hg) | 130.5 ± 19.8 | 128.1 ± 19.3 | 128.5 ± 19.4 |
Diastolic blood pressure (mm Hg) | 79.1 ± 12.4 | 78.6 ± 11.9 | 78.7 ± 12.0 |
Anti-hypertensive medication | 146(26.7%) | 503(18.1%) | 649(19.5%) |
Diabetes mellitus | 54(9.9%) | 220(7.9%) | 274(8.2%) |
Fasting plasma glucose (mmol/l) | 5.49 ± 1.23 | 5.55 ± 1.17 | 5.54 ± 1.17 |
HbA1c (%) | 5.22 ± 0.69 | 5.22 ± 0.66 | 5.22 ± 0.67 |
Glucose-lowering medication | 28(5.1%) | 117(4.2%) | 145(4.4%) |
Cardiovascular diseases | 34(6.2%) | 80(2.9%) | 114(3.4%) |
Total cholesterol (mmol/l) | 5.66 ± 0.88 | 5.46 ± 0.83 | 5.50 ± 0.88 |
HDL cholesterol (mmol/l) | 1.60 ± 0.41 | 1.64 ± 0.42 | 1.63 ± 0.42 |
Lipid-lowering medication | 68(12.5%) | 233(8.4%) | 301(9.1%) |
Uric acid (μmol/l) | 333 ± 89 | 303 ± 77 | 309 ± 83 |
Current smokers | 68(12.5%) | 495(17.8%) | 563(16.9%) |
Table 2
Genotype frequencies of study subjects
IL1B T-31C (rs1143627) | | | |
T T | 163 (29.9%) | 791 (28.5%) | 954 (28.7%) |
C T | 266 (48.7%) | 1,355 (48.8%) | 1,621 (48.8%) |
C C | 117 (21.4%) | 631 (22.7%) | 748 (22.5%) |
IL2 T-330G (rs2069762) | | | |
T T | 244 (44.9%) | 1,225 (44.1%) | 1,469 (44.2%) |
T G | 241 (44.3%) | 1,239 (44.6%) | 1,480 (44.6%) |
G G | 59 (10.9%) | 312 (11.2%) | 371 (11.2%) |
IL4 T-33C (rs2070874) | | | |
T T | 259 (47.4%) | 1,193 (43.0%) | 1,452 (43.7%) |
T C | 241 (44.1%) | 1,226 (44.2%) | 1,467 (44.2%) |
C C | 46 (8.4%) | 357 (12.9%) | 403 (12.1%) |
IL6 C-572G (rs1800796) | | | |
C C | 312 (57.1%) | 1,600 (57.6%) | 1,912 (57.6%) |
G C | 208 (38.1%) | 977 (35.2%) | 1,185 (35.7%) |
G G | 26 (4.8%) | 199 (7.2%) | 225 (6.8%) |
IL8 T-251A (rs4073) | | | |
T T | 254 (46.5%) | 1,281 (46.5%) | 1,535 (46.5%) |
A T | 235 (43.0%) | 1,204 (43.7%) | 1,439 (43.6%) |
A A | 57 (10.4%) | 273 (9.9%) | 330 (10.0%) |
IL10 T-819C (rs1800871) | | | |
T T | 252 (46.2%) | 1,175 (42.5%) | 1,427 (43.1%) |
C T | 239 (43.8%) | 1,222 (44.2%) | 1,461 (44.1%) |
C C | 55 (10.1%) | 370 (13.4%) | 425 (12.8%) |
IL13 C-1111T (rs1800925) | | | |
C C | 370 (67.9%) | 1,847 (66.5%) | 2,217 (66.8%) |
T C | 158 (29.0%) | 840 (30.3%) | 998 (30.1%) |
T T | 17 (3.1%) | 89 (3.2%) | 106 (3.2%) |
TNFA C-857T (rs1799724) | | | |
C C | 373 (68.3%) | 1,788 (64.4%) | 2,161 (65.0%) |
C T | 155 (28.4%) | 887 (31.9%) | 1,042 (31.4%) |
T T | 18 (3.3%) | 102 (3.7%) | 120 (3.6%) |
TNFA T-1031C (rs1799964) | | | |
T T | 383 (70.2%) | 1,934 (69.6%) | 2,317 (69.7%) |
C T | 144 (26.4%) | 764 (27.5%) | 908 (27.3%) |
C C | 19 (3.5%) | 79 (2.8%) | 98 (2.9%) |
CD14 T-260C (rs2569190) | | | |
T T | 144 (26.4%) | 785 (28.3%) | 929 (28.0%) |
T C | 275 (50.4%) | 1,412 (50.9%) | 1,687 (50.8%) |
C C | 127 (23.3%) | 580 (20.9%) | 707 (21.3%) |
The mean eGFRs and CKD prevalences were compared among the genotypes of the 10 cytokine SNPs (Table
3). The mean eGFRs differed for the
IL4 T-33C (rs2070874) and
IL6 C-572G (rs1800796) genotypes (P = 0.012 and P = 0.004, respectively), while the CKD prevalences differed for the
IL4 T-33C genotypes. Thus, the
IL4 and
IL6 genotypes were subjected to multivariate analyses.
Table 3
Mean eGFRs and CKD prevalence with respect to cytokine polymorphism genotypes
IL1B T-31C (rs1143627) | | | | | | | |
T T | 954 | 74.0 ± 14.9 | | | 163 | (16.6%) | |
C T | 1,621 | 73.9 ± 14.6 | 0.576 | | 266 | (16.3%) | 0.727 |
C C | 748 | 74.6 ± 15.3 | | | 117 | (15.6%) | |
IL2 T-330G (rs2069762) | | | | | | | |
T T | 1,469 | 74.0 ± 14.8 | | | 244 | (16.6%) | |
T G | 1,480 | 74.2 ± 14.9 | 0.860 | | 241 | (16.3%) | 0.938 |
G G | 371 | 74.3 ± 14.5 | | | 59 | (15.9%) | |
IL4 T-33C (rs2070874) | | | | | | | |
T T | 1,452 | 73.4 ± 14.6 | | | 259 | (17.8%) | |
T C | 1,467 | 74.4 ± 15.1 |
0.012
| | 241 | (16.4%) |
0.009
|
C C | 403 | 75.8 ± 14.5 | | | 46 | (11.4%) | |
IL6 C-572G (rs1800796) | | | | | | | |
C C | 1,912 | 74.2 ± 14.7 | | | 312 | (16.3%) | |
G C | 1,185 | 73.4 ± 14.8 |
0.004
| | 208 | (17.6%) | 0.082 |
G G | 225 | 76.9 ± 15.9 | | | 26 | (11.6%) | |
IL8 T-251A (rs4073) | | | | | | | |
T T | 1,535 | 74.1 ± 14.4 | | | 254 | (17.3%) | |
A T | 1,439 | 73.9 ± 15.2 | 0.745 | | 235 | (16.3%) | 0.917 |
A A | 330 | 74.6 ± 15.4 | | | 57 | (16.5%) | |
IL10 T-819C (rs1800871) | | | | | | | |
T T | 1,427 | 73.6 ± 14.7 | | | 252 | (17.7%) | |
C T | 1,461 | 74.2 ± 14.8 | 0.155 | | 239 | (16.4%) | 0.070 |
C C | 425 | 75.2 ± 15.0 | | | 55 | (12.9%) | |
IL13 C-1111T (rs1800925) | | | | | | | |
C C | 2,217 | 74.0 ± 14.9 | | | 370 | (16.7%) | |
T C | 998 | 74.3 ± 14.7 | 0.734 | | 158 | (15.8%) | 0.827 |
T T | 106 | 74.7 ± 14.3 | | | 17 | (16.0%) | |
TNFA C-857T (rs1799724) | | | | | | | |
C C | 2,161 | 73.6 ± 14.7 | | | 373 | (17.3%) | |
C T | 1,042 | 74.9 ± 15.0 | 0.054 | | 155 | (14.9%) | 0.212 |
T T | 120 | 75.5 ± 15.4 | | | 18 | (15.0%) | |
TNFA T-1031C (rs1799964) | | | | | | | |
T T | 2,317 | 73.9 ± 14.6 | | | 383 | (16.5%) | |
C T | 908 | 74.5 ± 15.4 | 0.641 | | 144 | (15.9%) | 0.652 |
C C | 98 | 74.1 ± 14.6 | | | 19 | (19.4%) | |
CD14 T-260C (rs2569190) | | | | | | | |
T T | 929 | 74.5 ± 14.5 | | | 144 | (15.5%) | |
T C | 1,687 | 74.2 ± 14.9 | 0.226 | | 275 | (16.3%) | 0.403 |
C C | 707 | 73.3 ± 14.9 | | | 127 | (18.0%) | |
Higher eGFRs and lower CKD prevalences were observed for the
IL4 -33CC and
IL6 -572GG genotypes (Table
4). The mean eGFRs were 75.7 and 73.4 ml/min/1.73 m
2 for the
IL4 CC and TT genotype carriers, and 76.9 and 74.2 ml/min/1.73 m
2 for the
IL6 GG and CC genotype carriers, respectively. The CKD prevalences were 11.4% and 17.8% for the
IL4 CC and TT genotype carriers (OR = 0.59, 95% CI = 0.37-0.95, P = 0.029 after adjustment), and 11.6% and 16.3% for the
IL6 GG and CC genotype carriers (OR = 0.67, 95% CI = 0.50-0.90, P = 0.008 after adjustment), respectively. These differences were greater when the two genotypes were combined (Table
5). Subjects with both the
IL4 CC and
IL6 GG genotypes showed the highest mean eGFR (79.1 ml/min/1.73 m
2) and lowest CKD prevalence (0.0%), while subjects carrying both the
IL4 TT and
IL6 CC genotypes showed the lowest mean eGFR (73.4 ml/min/1.73 m
2) and highest CKD prevalence (17.9%). There was no interaction between the
IL4 CC and
IL6 GG genotypes, and their effects were additive.
Table 4
Mean eGFRs and CKD prevalence for IL4T-33C and IL6C-572G genotypes
IL4 T-33C | | | | | | | | | | | | |
| TT | 1,452 | 73.4 ± 14.6 | 0 | (reference) | - | | 259 | (17.8%) | 1 | (reference) | - |
| TC | 1,466 | 74.4 ± 15.1 | 0.9 | (-1.2-2.9) | 0.346 | | 241 | (16.4%) | 0.91 | (0.78-1.07) | 0.269 |
|
CC
| 403 | 75.7 ± 14.5 | 2.2 | (-1.9-6.3) | 0.240 | | 46 | (11.4%) |
0.59
| (0.37-0.95) | 0.029 |
IL6 C-572G | | | | | | | | | | | | |
| CC | 1,911 | 74.2 ± 14.7 | 0 | (reference) | - | | 312 | (16.3%) | 1 | (reference) | - |
| CG | 1,185 | 73.4 ± 14.8 | -1.1 | (-2.3-0.1) | 0.065 | | 208 | (17.6%) | 1.13 | (0.98-1.31) | 0.091 |
|
GG
| 225 | 76.9 ± 15.9 | 2.6 | (-0.1-5.2) | 0.055 | | 26 | (11.6%) |
0.67
| (0.50-0.90) | 0.008 |
Table 5
Mean eGFRs and CKD prevalence for IL4T-33C and IL6C-572G genotypes combined
IL4 TT/ |
IL6 CC | 849 | 73.4 ± 14.4 | 0 | (reference) | - | | 152 | (17.9%) | 1 | (reference) | - |
IL4 TC/ |
IL6 CC | 854 | 74.5 ± 14.9 | 1.1 | (-0.3-2.4) | 0.108 | | 140 | (16.4%) | 0.89 | (0.75-1.06) | 0.200 |
IL4 TT/ |
IL6 CG | 512 | 72.5 ± 14.5 | -0.8 | (-2.8-1.1) | 0.337 | | 98 | (19.1%) | 1.08 | (0.90-1.30) | 0.387 |
IL4 TC/ |
IL6 CG | 512 | 74.0 ± 15.2 | 0.2 | (-3.1-3.5) | 0.890 | | 84 | (16.4%) | 0.94 | (0.68-1.28) | 0.686 |
IL4 CC / |
IL6 CG | 161 | 74.0 ± 14.4 | 0.3 | (-3.8-4.4) | 0.867 | | 26 | (16.1%) | 0.89 | (0.42-1.90) | 0.768 |
IL4 TC/ |
IL6
GG
| 100 | 75.6 ± 17.0 | 2.1 | (-1.5-5.7) | 0.217 | | 17 | (17.0%) | 0.94 | (0.67-1.32) | 0.720 |
IL4 CC / |
IL6 CC | 208 | 76.5 ± 14.6 | 3.1 | (-1.2-7.4) | 0.127 | | 20 | (9.6%) |
0.48
| (0.39-0.58) | < 0.001 |
IL4 TT/ |
IL6
GG
| 91 | 77.6 ± 15.4 |
4.2
| (0.4-8.1) | 0.036 | | 9 | (9.8%) |
0.49
| (0.37-0.63) | < 0.001 |
IL4 CC / |
IL6
GG
| 34 | 79.1 ± 13.4 |
5.2
| (0.3-10.2) | 0.041 | | 0 | (0.0%) |
0.00
| - | - |
We previously reported an association between the
CD14 A-260G SNP and kidney function among a population living in the north part of Japan using an eGFR derived from the MDRD Study equation [
14]. However, the present study did not show such an association.
Discussion
Our explorations revealed that the subjects with the genotypes IL4 -33CC (a genotype that produces high levels of IL-4) and IL6 -572GG (a genotype that produces low levels of IL-6) had better kidney function and a lower risk of CKD in a large Japanese population.
Cytokines are important modulators of inflammation, and the balance between pro- and anti-inflammatory cytokines determines the inflammatory response and may mediate the progression of atherosclerosis and subsequent CKD [
6,
7]. Genetic polymorphisms of these cytokines have been shown to be associated with comorbidities, such as cardiovascular disease, in ESRD patients [
3‐
5], or with ESRD susceptibility [
8], but there are controversial results that no polymorphisms of the
IL6,
IL10, and
IL1 genes were associated with ESRD [
11]. The evidence for polymorphisms in cytokine genes affecting the risk of CKD itself is scarce and this issue has not been fully clarified, especially in the general population.
IL-4 is an anti-inflammatory cytokine that exerts immunosuppressive effects on macrophages and suppresses pro-inflammatory cytokine production [
21]. The promoter polymorphism
IL4 T-33C (which is in complete linkage disequilibrium with
IL4 T-589C) affects IL-4 expression [
15], and the CC genotype shows a high level of IL-4 protein [
9]. Accordingly, subjects with the CC genotype showed a lower risk of ischemic stroke relapse [
22], consistent with our data indicating a lower risk of CKD in CC genotype carriers.
An elevated level of the main pro-inflammatory cytokine IL-6 predicts cardiovascular mortality in ESRD patients [
3]. The
IL6 C to G variation at position -572 reduces the transcriptional activity of the
IL6 promoter, and the levels of IL-6 are lower in carriers of the
IL6 -572GG genotype [
10,
11]. Accordingly, the
IL6 -572GG genotype was associated with lower risks of kidney allograft survival [
23] and abdominal aortic aneurysm [
24], consistent with our data showing a lower risk of CKD in GG genotype carriers.
The combined effect of high IL-4- and low IL-6-producing genotypes has been shown to lead to a lower risk of ESRD [
8]. We also found that no CKD subjects carried high IL-4- and low IL-6-producing (low-risk) genotypes, and that their mean eGFR was 5.2 ml/min/1.73 m
2 higher than that in carriers of the low IL-4- and high IL-6-producing (high-risk) genotypes. This difference is almost equivalent to a 14-year difference in a healthy Japanese population [
25], and has a significant impact with respect to cardiovascular disease prevention, especially among healthy individuals who are not aware of a possible risk of CKD.
The evidence for polymorphisms in cytokine genes affecting the risk of CKD is scarce. No cytokine genes were identified as susceptibility loci for CKD in a Caucasian population in a genome-wide association study (GWAS) [
1]. However, this may simply mean that no cytokine genes were highly statistically significantly associated in the context of the multiple testing related to the GWAS, and therefore not presented in the GWAS report. Yoshida
et al. [
2] showed that some genetic variants were associated with CKD in a large Japanese population, but only
TNFA and
IL10 were included as representative cytokine genes and did not show associations. In contrast, we selected candidate genes that are assumed to be of physiological interest based on the associations between pro-/anti-inflammatory cytokines and CKD [
6,
7]. The other difference is that the former study participants were mixed, and comprised patients with various symptoms, health check-up examinees and aged subjects [
2]. In contrast, our study participants were enrolled from the population with an age range of 35 to 69. Thus, our study contains the largest general Japanese population investigated to date for associations among pro-/anti-inflammatory cytokine gene variants and CKD.
No haplotype analyses were needed because
IL4 T-33C and
IL6 C-572G are the only SNPs that affect the IL-4 and IL-6 levels in Japanese subjects.
IL4 T-589C,
IL4 T-33C, and a 70-bp variable number of tandem repeat polymorphism (VNTR) within intron 3 are in complete linkage disequilibrium, thus there are only two
IL4 gene haplotypes in Japanese populations; -589T/-33T/B1 (183 bp) (allele frequency, 0.670) and -589C/-33C/B2 (253 bp) (0.330) [
15]. In addition,
IL6 transcription is influenced by four promoter polymorphisms (C-572G, A-597G, -373AnTn and C-174G) [
26], but A-597G and C-174G do not exist or are very rare in Japanese populations. Only three prevalent haplotypes have been identified in Japanese populations [
10]: -572C/-373A10T10 (allele frequency 0.733), G/A10T11 (0.136), and G/A9T11 (0.104). The serum levels of IL-6 were high in C/A10T10 and low in both G/A10T11 and G/A9T11, with no difference between the IL-6 levels in G/A10T11 and G/A9T11. Thus,
IL4 T-33C and
IL6 C-572G could be the only SNPs that affect the transcriptional activity of IL-4 and IL-6 in Japanese populations.
A limitation of our study was that
IL6 C-572G was not in Hardy-Weinberg equilibrium. However, the absolute difference between the actual and expected frequencies was only 1%. Thus, the errors in genotyping seem unlikely to result in substantial misclassification [
13], although the large number in the study population might account for the statistically significant deviation from Hardy-Weinberg equilibrium. Another limitation is the possible misclassification of CKD subjects owing to the single measurement of SCr. As our subjects were presumably healthy volunteers or health check-up examinees, their kidney function might have been stable. Thus, the possibility that a single measurement of SCr could result in misclassification is low. Since we lacked a replication cohort, adjustment of the p-values for the multiple comparisons, and biomarkers of inflammation, further confirmation using another cohort of subjects is needed so that there is a high chance that our study results represent a false positive finding. As this was a cross-sectional study, a prospective study is needed to further confirm the decrease in eGFR and the incident risk of CKD.
Acknowledgements
The authors thank Kyota Ashikawa, Tomomi Aoi and other members of the Laboratory for Genotyping Development, Center for Genomic Medicine, RIKEN, for support with genotyping, and Yoko Mitsuda, Keiko Shibata and Etsuko Kimura at the Department of Preventative Medicine, Nagoya University Graduate School of Medicine, for their technical assistance. This study was supported in part by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (Nos. 17015018 and 221S0001).
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
RO analyzed data and mainly drafted the article. KW, MN, KA, and MK were involved in drafting the manuscript and revising it critically for important intellectual content. EM, SK, MH, NT, SS, TT, KO, HH, KM, and HM made substantial contributions to the conception, design, and acquisition of data. NH and HT initiated the study and gave final approval of the version to be published. All the authors have read and approved the final manuscript.